Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 31, 2018

Varian Medical to purchase Sirtex for $1.28bn

US-based Varian Medical Systems has entered an agreement to purchase all outstanding shares of Australian life sciences firm Sirtex Medical for about A$1.58bn ($1.28bn).

US-based Varian Medical Systems has entered an agreement to purchase all outstanding shares of Australian life sciences firm Sirtex Medical for about A$1.58bn ($1.28bn).

The deal is in line with Varian’s strategy for long-term growth and is expected to strengthen the firm’s position in radiation medicine and interventional oncology segments.

Varian plans to combine its expertise in treatment planning and delivery, image guidance and processing, oncology practice management software, and radiation safety with Sirtex’s interventional oncology platform to deliver better care solutions for cancer patients.

Varian Medical Systems CEO Dow Wilson said: “This acquisition is the latest step in Varian’s long-term strategy to become a global leader in multi-disciplinary integrated cancer care solutions.

“The combination of the two companies will expand the reach of the Sirtex platform by making it more broadly available to the clinical community.

“The combination of the two companies will expand the reach of the Sirtex platform by making it more broadly available to the clinical community.”

“Our companies share a common vision of a world without fear of cancer, and we look forward to completing this acquisition and positively impacting more patients’ lives around the world.”

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

Sirtex’s lead product SIR-Spheres Y-90 resin microspheres is a targeted internal radiation therapy indicated for certain types of liver cancers in more than 40 countries.

With operations in the US, Europe, and Asia, the firm has reported annual revenues of A$234m ($189.13m) in the fiscal year ending on 30 June 2017.

Set to be completed in late May this year, the transaction is subject to shareholders and regulatory approvals, as well as other customary closing conditions.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU